Ipsen and Inspiration Biopharmaceuticals to create haemophilia portfolio
French pharmaceutical firm Ipsen and US haemophilia specialist Inspiration Biopharmaceuticals are to develop a portfolio of haemophilia drugs that could yield sales of US$1bn over the next 10 years.
French pharmaceutical firm Ipsen and US haemophilia specialist Inspiration Biopharmaceuticals are to develop a portfolio of haemophilia drugs that could yield sales of US$1bn over the next 10 years.
Ipsen will first take a 20% stake in Inspiration for US$85m and could increase this to 47% for milestone payments of up to US$174m based on the successful development of leading product candidates IB1001 and OBI-1, which are scheduled to begin Phase III clinical testing this year.
Upon certain triggering events, Ipsen could acquire full control of Inspiration.
The deal is expected to close in the first quarter of 2010.
Under the terms of the agreement, Ipsen will provide up to US$259m of funding to Inspiration for further development of IB1001 and OBI-1.
John Taylor, co-founder of Inspiration, said the addition of OBI-1 would make the company a worldwide leader in haemophilia "providing a broad range of treatment options for individuals suffering from bleeding disorders".
